Our strategic pivot towards high-value businesses gained significant traction in FY 2026, strengthening our earnings and building a resilient portfolio. Specialty Chemicals accounts for 75% of overall EBITDA, up from 67% in FY 2025 and 54% in FY 2024, reflecting a sustained evolution in our business mix. This performance is not driven by short-term pricing cycles, but by deeper customer partnerships, scale-up of high-margin platforms, operational excellence, and a sharper focus on specialised solutions.

With Specialty Chemicals EBITDA margins consistently remaining above 25% for six consecutive quarters, we have demonstrated that our transformation is structural, sustainable, and built for long-term growth.